Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on October 1, 2026 and October 14, 2026 to a total of 26 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Covered in this story
What has happened since
- Madrigal Pharmaceuticals Inc is up 1.1% since this was published, 4 days ago.
- Associated Bancorp is up 1.0% since this was published, 4 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $MDGL yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Madrigal Pharmaceuticals Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.